Publication number: 20250145722
Abstract: Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and/or proteins associated with neurological diseases and/or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and/or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.
Type:
Application
Filed:
January 10, 2025
Publication date:
May 8, 2025
Inventors:
Dongxu Sun, Suhail Rasool, Catherine A. Gordon, Ke Hong, Fan Chen, Sara Matilda Bolin, Ksenya Shchors, Yadong Yu, Tsung-Huang Tsai, Samuel A.F. Williams, Karan Lala, Heng Wu, Yan Wang